ImmunityBio, Inc. (IBRX) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Heavy Cash Burn ⢠Negative Equity IBRX has strong liquidity and exceptional gross margins, but persistent losses, negative equity, heavy dilution, and ongoing cash burn make the stock financially risky despite its high sales-based valuation.
Price Behavior
Key Price Behavior Insights: ⢠Downtrend intact ⢠Support holding ⢠Rally fading Support Level: $6.92 Resistance Level: $7.25-$7.30 Over the last month, IBRX remains in a short-term downtrend, but holding near $6.92 support suggests a tentative base as rallies still face resistance at $7.25-$7.30.
Sentiment & News
Key News Insights: ⢠Class-action overhang ⢠FDA catalyst watch ⢠Execution risk IBRX headlines were dominated by repeated securities class-action notices, while a later outlook piece refocused attention on FDA review timing, Anktiva demand, and execution risk.
AI Summary
IBRX has shifted from a pure biotech speculation to a real commercialization story thanks to ANKTIVA's strong revenue growth, but the investment case still hinges on whether that momentum can outpace heavy losses, dilution, high debt, and litigation before the market will re-rate it.
Description
ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines targeting cancers and infectious diseases. The company applies multiple immunotherapy and cell therapy approachesâincluding engineered cytokine fusion proteins, synthetic immunomodulators, and both natural killer and T-cell platformsâand has candidates in Phase II/III trials for solid and liquid tumors (for example, bladder, pancreatic and lung cancers) as well as antiviral programs for pathogens such as SARS-CoV-2 and HIV. It maintains research collaborations and licensing arrangements with U.S. government institutes and several biopharma partners and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 2 | Mar 9 | IBRX | ImmunityBio, Inc. | ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play. | Closed | -19.1% |
| Feb 19 | Feb 26 | IBRX | ImmunityBio, Inc. | Multiple recent regulatory wins (EU conditional approval for ANKTIVA+BCG on 2026-02-18, Saudi approval, FDA Type B meeting) plus an EU commercialization deal and accelerating product revenue (~$38M quarter) have driven a >200% month-long rally; momentum remains strong into further catalyst and financing headlines despite high risk. | Closed | +10.9% |
| Jan 16 | Jan 23 | IBRX | ImmunityBio, Inc. | ImmunityBio is a hot idea driven by accelerating commercial revenue growth (700% annual increase in 2025), regulatory approvals expanding markets, positive clinical data mid-January 2026, nearly doubled stock price in past month, despite ongoing financial risks. | Closed | +16.9% |